Hikma Pharmaceuticals USA Inc. is seeking an additional month to submit its petition to the United States Supreme Court. This request comes in the wake of a decision by the Federal Circuit to reinstate a lawsuit. The suit accuses Hikma of allegedly inducing physicians to infringe upon patents related to Amarin Pharma Inc.’s cardiovascular medication, Vascepa. The company has cited the significance of the case and the demanding schedules of its legal team as reasons for the extension.
For further details on this development, visit the article [here](https://www.law360.co.uk/articles/2278830/hikma-wants-extension-at-high-court-in-skinny-label-case) in Law360.